BofA Securities: Upgraded Kangfang Bio (09926) Target Price to HKD 164, Reiterated "Buy" Rating.

The Wisdom Financial APP learned that Bank of America Securities released a research report stating that Kangfang Biotech (09926) presented the overall survival analysis of the HARMONi-6 study at the oral Plenary Session of the ASCO 2026 Annual Meeting, marking the first time in the 61-year history of ASCO that a Chinese-original oncology innovative drug was selected for the Plenary Session. The bank has raised Kangfang Biotech's revenue forecast for 2026-2028 by 1.7%/1.5%/1.1%, and net profit forecast by 10.9%/2.8%/3.6%. The target price has been adjusted from HK$162.8 to HK$164, with a reiteration of a "buy" rating. Reasons for optimism include solid clinical data and multiple upcoming pipeline catalysts.